Showing 41-50 of 3001 results for "".
- Rescuing MS Patients From the HMO Undertowhttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN0405HMO-Undertow-pdf/31465/Navigating Insurance Challenges in Multiple Sclerosis CareManaging multiple sclerosis (MS) has become increasingly complex due to stringent insurance policies and rising patient co-pays, posing significant challenges for both neurologists and their patients. Recent trends show that managed care comp
MS Minute: Disparities in Multiple Sclerosis: Incorporating Equity Into Clinical Care and Research
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-disparities-in-multiple-sclerosis-incorporating-equity-into-clinical-care-and-research/32018/Assessing biologic, genetic, and social factors of patients with MS to shrink the gap in care for underrepresented populations.Fresh Approaches to MS Care
https://practicalneurology.com/columns/practice-management/fresh-approaches-to-ms-care/30712/New treatment options encourage a fresh approach to patients.MS Minute: Retinal Optical Coherence Tomography for MS
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-retinal-optical-coherence-tomography-for-ms/31939/How optical coherence tomography interpretation can aid care for multiple sclerosis.Discussing Disparities in MS Care for Underrepresented Populations
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/discussing-disparities-in-ms-care-for-underrepresented-populations/30085/In this episode, Trisham Gyang, MD, Clinical Assistant Professor of Neurology, The Ohio State University Wexner Medical Center, and Gopika Govindan Kutty, MD, Fellow, Department of Neurology, The Ohio State University Wexner Medical Center, provide strategies to assess biologic, genetic, and socialMS Minute: A Brief History of MS Care
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-a-brief-history-of-ms-care/31957/“The secret of the care of the patient is in caring for the patient.”—Dr. Francis PeabodyMS Minute: Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease/32180/MOGAD, an inflammatory demyelinating disease of the central nervous system, has some overlapping clinical features with NMOSD and MS but is a distinct entity with unique pathologic, clinical, and imaging features.- Making the Switch: When and How to Step-Up MS Therapyhttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN1108MS-pdf/30974/Advancements and Considerations in Multiple Sclerosis TherapeuticsOver the past quarter-century, Multiple Sclerosis (MS) treatment has evolved rapidly, marked by the FDA approval of six disease-modifying therapies (DMTs) with several more in development. This acceleration contrasts with the decade-l
Recognize and Prevent Polypharmacy in MS Patients
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/recognize-and-prevent-polypharmacy-in-ms-patients/30836/Minimizing drug-to-drug interactions is paramount in finding an appropriate treatment regimen, ensuring safety, and encouraging good quality of life.MS Minute: The COVID-19 Vaccine & Vaccine Readiness in MS
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-the-covid-19-vaccine-vaccine-readiness-in-ms/31748/Evidence suggests all people with multiple sclerosis, including those on any class of disease-modifying treatment, can and should be vaccinated against COVID-19.